FDA clears test to manage potential kidney transplant rejection

Article

The FDA has cleared a test to help manage potential organ rejection in kidney transplant patients.

The FDA has cleared a test to help manage potential organ rejection in kidney transplant patients.

The test, called QMS Everolimus Immunoassay, monitors the blood level of everolimus (Zortress), a drug that helps prevent rejection in kidney transplants.

"QMS Everolimus is the first FDA-cleared test physicians can use to maintain appropriate levels of the immunosuppressant everolimus," said Jeffrey Shuren, MD, JD, director of the FDA’s Center for Devices and Radiological Health.

Thermofisher, the manufacturer of QMS Everolimus, demonstrated the performance of the test by comparing results from the new test with the results from everolimus reference tests used in the clinical trial of everolimus. When the clinical trial blood samples were tested with QMS Everolimus, the results, on average, were similar to those of the clinical trial reference test.

Related Videos
Leonardo Kayat Bittencourt, MD, PhD, answers a question during a Zoom video interview
blur image background of corridor in hospital or clinic image | Image Credit @ whyframeshot - stock.adobe.com
Male and female surgeon performing surgery | Image Credit: © Georgii - stock.adobe.com
 Licensed   FILE #:  458906503  Preview Crop  Find Similar  Expand Image DIMENSIONS 8000 x 5333px FILE TYPE JPEG CATEGORY The Environment LICENSE TYPE Standard or Extended A lake in the shape of a recycling sign in the middle of untouched nature | Image Credit: © malp - stock.adobe.com
Dr. Mehmet Asim Bilen in an interview with Urology Times
Anne M. Suskind, MD, MS, FACS, FPMRS, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.